{"entity":{"id":"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","aka":[],"tldr":"Adding bevacizumab to single-agent chemotherapy for platinum-resistant ovarian cancer doubled the time to progression and more than doubled the response rate, without a significant gain in survival.","summary":"Open-label randomised phase 3 trial: 361 women with platinum-resistant recurrent ovarian cancer received the investigator's choice of weekly paclitaxel, pegylated liposomal doxorubicin or topotecan, alone or with bevacizumab.\n\nMedian progression-free survival was 6.7 months with bevacizumab against 3.4 months (hazard ratio 0.48, p < 0.001); response rate 27.3 against 11.8 percent; median overall survival 16.6 against 13.3 months (hazard ratio 0.85, p 0.174). Grade 2 or higher hypertension and proteinuria were more common with bevacizumab; gastrointestinal perforation occurred in 2.2 percent.","asOf":"2026-09-22","links":[{"label":"J Clin Oncol 2014","url":"https://doi.org/10.1200/JCO.2013.51.4489"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24637997/"}],"tags":[],"related":[],"cancers":["platinum-resistant-ovarian-cancer","ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["aurelia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2014,"doi":"10.1200/JCO.2013.51.4489","pmid":"24637997","authors":"Pujade-Lauraine E, Hilpert F, Weber B, et al.","paperType":"rct","findings":["Median progression-free survival 6.7 versus 3.4 months; hazard ratio 0.48 (95% CI 0.38 to 0.60), p < 0.001.","Objective response 27.3 versus 11.8 percent (p 0.001).","Median overall survival 16.6 versus 13.3 months; hazard ratio 0.85 (0.66 to 1.08), not significant."],"whatItMeans":"Bevacizumab with weekly paclitaxel, liposomal doxorubicin or topotecan is a standard option in platinum-resistant ovarian cancer; approved in the United States in 2014.","caveats":["Open-label; patients with more than two prior regimens or bowel involvement at risk of perforation were excluded.","Crossover to bevacizumab at progression diluted the survival comparison."],"changedPractice":true,"participants":361},"route":"/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"trial":[{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}